HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

CH 4893237

an estrogen receptor downregulator that may serve as second-line hormone treatment for breast cancer; structure in first source

Also Known As:

CH-4893237; CH4893237

Networked: 2 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Polycyclic Compounds: 6
- Fused-Ring Compounds
  - Steroids: 70059
    - Estranes
      - Estrenes
        Estradiol: 14115
        CH 4893237: 2
Hormones, Hormone Substitutes, and Hormone Antagonists
- Hormones: 80400
  - Gonadal Hormones: 716
    - Gonadal Steroid Hormones: 7657
      - Estradiol Congeners: 358
        Estradiol: 14115
        CH 4893237: 2

Experts

1.	Kanbe, Yoshitake: 2 articles (03/2009 - 08/2005)
2.	Morikawa, Kazumi: 2 articles (03/2009 - 08/2005)
3.	Taniguchi, Kenji: 2 articles (03/2009 - 08/2005)
4.	Tsunenari, Toshiaki: 2 articles (03/2009 - 08/2005)
5.	Yamada-Okabe, Hisafumi: 2 articles (03/2009 - 08/2005)
6.	Yoneya, Takaaki: 2 articles (03/2009 - 08/2005)
7.	Kwon, Lae-Sung: 1 article (03/2009)
8.	Lee, Mee-Hyun: 1 article (03/2009)
9.	Lee, Yeon-Ho: 1 article (03/2009)
10.	Saito, Hidemi: 1 article (08/2005)

Related Diseases

1.	Breast Neoplasms (Breast Cancer) 03/01/2009 - "Therefore, CH4893237 alone or in combination with an aromatase inhibitor may be an efficient treatment for postmenopausal breast cancer patients." 08/01/2005 - "Thus, CH4893237 will provide an additional option for second-line hormone treatment of breast cancer." 03/01/2009 - "Effects of CH4893237, a new orally active estrogen receptor downregulator, on breast cancer xenograft models with low serum estrogen levels." 03/01/2009 - "We compared the antitumor efficacy and estrogen receptor (ER) degradation of CH4893237, a new orally active selective ER downregulator, with fulvestrant and tamoxifen in human breast cancer xenografts with low levels of serum estrogen (E2) (50.6, 22.9 and <16.7 pg/ml), equivalent to the ranges in postmenopausal or aromatase inhibitor-treated breast cancer patients. "
2.	Neoplasms (Cancer) 03/01/2009 - "In Br-10 xenografts with ovariectomized-level E2 (<16.7 pg/ml), tamoxifen (30 mg/kg) increased the tumor volume but CH4893237 (30 mg/kg) showed no agonistic activity. "

Related Drugs and Biologics

1.	Aromatase Inhibitors
2.	Tamoxifen
3.	Estrogen Receptors
4.	Hormones (Hormone)
5.	Estrogens (Estrogen)
6.	Fulvestrant (Faslodex)